August 23, 2023
- August 01, 2023 - Network of Genomics-Enabled Learning Health Systems (gLHS) – Clinical Sites (U01 Clinical Trial Required). See RFA-HG-23-041
National Cancer Institute (NCI)
The purpose of this Notice is to inform potential applicants that the National Cancer Institute (NCI) will participate, effective immediately, in RFA-HG-23-041 "Network of Genomics-Enabled Learning Health Systems (gLHS) – Clinical Sites (U01, Clinical Trial Required)”.
The following changes and updates (as indicated in bold italics) are made to RFA-HG-23-041 to reflect participation of NCI in this NOFO.
Part 1. Overview Information
Components of Participating Organizations
National Human Genome Research Institute (NHGRI)
National Cancer Institute (NCI)
Catalog of Federal Domestic Assistance (CFDA) Number(s)
93.361, 93.837, 93.838, 93.839, 93.840, 93.233, 93.213, 93.121, 93.867, 93.242, 93.279, 93.273, 93.307, 93.393, 93.398, 93.399
Section II. Award Information
Funds Available and Anticipated Number of Awards
NHGRI proposes to commit $3,700,000 per year total costs for five years to support 4-6 gLHS Clinical Sites.
NCI proposes to commit $650,000 per year total costs for five years to support one (1) gLHS Clinical Site.
Part 2. Section VII. Agency Contacts
Scientific/Research Contacts
Nonniekaye Shelburne, MS, CRNP, AOCN
National Cancer Institute (NCI)
Telephone: 301-276-6897
Email: [email protected]
Financial/Grants Management Contacts
Crystal Wolfrey
National Cancer Institute (NCI)
Telephone: 240-276-6277
Email: [email protected]
All other sections of RFA-HG-23-041 remain unchanged.
Nonniekaye Shelburne, MS, CRNP, AOCN
National Cancer Institute (NCI)
Telephone: 301-276-6897
Email: [email protected]
and Human Services (HHS)
